Clinical trials: Colchicine
Non ST-Segment Elevation Myocardial Infarction
Short-Term Outcomes of Early Administration of Colchicine in Non-ST Segment Elevation Myocardial Infarction Patients Treated With Drug-Eluting Stents.
Inflammation plays a central role in the pathophysiology of atherosclerosis and in the progression of coronary artery. Colchicine, an anti-inflammatory agent traditionally used for gout and pericarditis, has emerged as a…
- Trial name
- NCT07143136
- Testing
- Colchicine
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Assiut University
Diabetic Nephropathy
Colchicine for Diabetic Nephropathy
Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function…
- Trial name
- NCT01005121
- Testing
- colchicine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof.Avi Livneh
COVID-19
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement…
- Trial name
- COLCOVID (NCT04328480)
- Testing
- Colchicine, Local standard of care
- Where
- Argentina
- Volunteers
- 1,279 people
- Sponsor
- Estudios Clínicos Latino América
Corona Virus Disease 19 (Covid 19)
The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention
Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question arises whether colchicine, administered in a…
- Trial name
- GRECCO-19 (NCT04326790)
- Testing
- Colchicine, Standard treatment
- Where
- Greece
- Volunteers
- 105 people
- Sponsor
- National and Kapodistrian University of Athens
Pericarditis Idiopathic Recurrent
Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis
Among patients with colchicine-resistant glucocorticoid-dependent idiopathic RP (idiopathic recurrent pericarditis during at least a second recurrence, having met the 2015 European Society of Cardiology criteria for pericarditis…
- Trial name
- RESTORE (NCT05737680)
- Testing
- Hydroxychloroquine, Colchicine
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- Hippocration General Hospital
Healthy
Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce
The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and sprinkled on applesauce (1 tablespoon) relative to the same dose given as…
- Trial name
- NCT01130051
- Testing
- Colchicine 0.6 mg tablet
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Venous Thromboembolism
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
This trial seeks to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients…
- Trial name
- NCT06440694
- Testing
- Colchicine 0.5 mg po
- Where
- 4 sites in Canada
- Volunteers
- 150 people
- Sponsor
- Ottawa Hospital Research Institute
Hypertension
The COlchicine HypERtENsion Trial
The purpose of this study to investigate the effects of colchicine on measures of vascular and cardiac function in patients with hypertension.
- Trial name
- COHERENT (NCT04916522)
- Testing
- Colchicine
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Herlev and Gentofte Hospital
Coronary Artery Disease
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
The main aim of this trial is to determine whether there are fewer cardiovascular events when patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of optimal standard treatment after…
- Trial name
- COL BE PCI (NCT06095765)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 19 sites in Belgium
- Volunteers
- 2,770 people
- Sponsor
- AZ Sint-Jan AV
Familial Mediterranean Fever, FMF
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
The purpose of this study is to assess safety and efficacy of the long-term treatment with RPH-104 at doses of 80 or 160 mg once every 2 weeks (q2w) in patients with familial Mediterranean fever (FMF) with colchicine resistance…
- Trial name
- NCT05190991
- Testing
- RPH-104
- Where
- 8 sites in Armenia, Russia and 1 more
- Volunteers
- 60 people
- Sponsor
- R-Pharm International, LLC
Chronic Hepatitis C
Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis
The rate of sustained virological response to a course of standard antiviral therapy (peg-interferon plus ribavirin) of patients with chronic hepatitis C infected by genotype 1 with advanced fibrosis (>F2) is rather low.
- Trial name
- RIBACIR (NCT00840489)
- Testing
- Ribavirin, Colchicine
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Oral Aphthae
Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae
The purpose of this study is to determine whether low doses of prednisolone, or colchicine are effective in the treatment of oral aphthae.
- Trial name
- NCT00723268
- Testing
- Prednisolone, Colchicine
- Where
- Iran
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mashhad University of Medical Sciences
Behçet's Syndrome
Withdrawal of Colchicine in Behçet Syndrome
Behçet's syndrome is a multisystem variable vessel vasculitis. Clinical features include mucocutaneous manifestions such as oral ulcers, genital ulcers, papulopustular lesions and nodular lesions, musculoskeletal manifestations…
- Trial name
- NCT06146192
- Testing
- Colchicine
- Volunteers
- 130 people
- Sponsor
- Istanbul University - Cerrahpasa
Acute Coronary Syndrome
MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
The previous Mono Antiplatelet and Colchicine Therapy (MACT) pilot study (NCT04949516) demonstrated that it was feasible to discontinue aspirin therapy and administer low-dose colchicine on the day after percutaneous coronary…
- Trial name
- MACT II (NCT06543082)
- Testing
- Colchicine 0.6 mg
- Where
- 9 sites in South Korea
- Volunteers
- 490 people
- Sponsor
- CHA University
Stroke, Stroke, Ischemic
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.
- Conditions
- Stroke, Stroke, Ischemic, Atherosclerosis, Myocardial Infarction
- Trial name
- RIISC-THETIS (NCT05476991)
- Testing
- Colchicine 0.5 MG, Ticagrelor 90mg, Aspirin 75-300mg
- Where
- France
- Volunteers
- 2,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Heart Disease, Percutaneous Coronary Intervention
Efficacy and Safety of Colchicine After PCI
Colchicine (0.5 mg/day) was recommended by the U.S. Food and Drug Administration in 2023 for the anti-inflammatory treatment of coronary heart disease (CHD). However, colchicine is still not approved for CHD treatment in China.
- Conditions
- Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
- Trial name
- NCT06472908
- Testing
- Colchicine 0.5 mg, Colchicine 0.375 mg
- Where
- 36 sites in China
- Volunteers
- 8,862 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Covid19, Pulmonary Fibrosis Interstitial
Colchicine and Post-COVID-19 Pulmonary Fibrosis
Pulmonary fibrosis is a sequela to adult respiratory distress syndrome (ARDS). 40% of patients with corona virus disease 2019 (COVID-19) develop ARDS, and 20% of them are severe.
- Trial name
- NCT04818489
- Testing
- Colchicine 0.5 MG, the standard protocol only
- Where
- Egypt
- Volunteers
- 260 people
- Sponsor
- ClinAmygate
Coronary Artery Disease
Colchicine Use for Primary Prevention of Coronary Artery Disease
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its…
- Trial name
- NCT05175274
- Testing
- Colchicine
- Where
- China
- Volunteers
- 6,792 people
- Sponsor
- Qingdao Central Hospital
Periprocedural Myocardial Infarction, Periprocedural Myocardial Injury
Colchicine for Reduction of Periprocedural Myocardial Injury in Percutaneous Coronary Intervention
Study of role of colchicine in reducing periprocedural myocardial injury in patients prepared for elective PCI and its role in reduction of MACEs.
- Trial name
- NCT05745818
- Testing
- Colchicine Pill
- Volunteers
- 300 people
- Sponsor
- Sohag University
Urothelial Cancer, Metastatic Solid Tumor
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
This open-label, non-randomized study aims to determine the anti-inflammatory effect of colchicine on the reduction of peripheral blood CRP in patients with solid tumors or localized urothelial cancer.
- Trial name
- NCT05279690
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Icahn School of Medicine at Mount Sinai